Suven Pharmaceuticals Ltd had reported a 12.2 percent year-on-year (YoY) rise in net profit at Rs 120.6 crore for the first quarter that ended June 30, 2023

Suven Pharma Q2 results: Net profit declines 5.3% YoY to Rs 74.72 crore

Private equity firm Advent International has acquired 50.1% stake in Suven Pharma at an agreed price of Rs 495/share.

Suven Pharma Gets New Board After Acquisition By Advent International

India Business News: The Cabinet Committee on Economic Affairs (CCEA) has approved a foreign direct investment (FDI) of up to Rs 9,589 crore by Cyprus-based Berhyanda Ltd

Cabinet okays FDI of up to Rs 9,589 crore for 76.1% stake in Hyderabad-based Suven Pharma - Times of India

The CCEA approval is for the acquisition of up to 76.1 per cent equity shares of Suven Pharmaceuticals Limited, a public limited Indian pharmaceutical company listed on the NSE and BSE, by Berhyanda Limited, Cyprus

CCEA Clears Berhyanda’s Foreign Investment Proposal of Rs 9,589 Crore In Suven Pharma; Check Details - News18

The highlight of Suven Pharma’s Q1 earnings was the company’s sharp margin improvement

Suven Pharma gains on healthy Q1 show, strong operational performance

Buzzing stocks for Friday: Reliance Industries, Indian Bank, Hindustan Zinc, Texmaco Rail, Suven Pharma, Schneider Electric, Siemens, RVNL, DLF, Adani Power, Delivery, Finolex Cables, Cholamandalam Investment, S Chand & Co, Aditya Birla Money

Stocks to watch today — April 21, 2023

Stocks to Watch today: HCLTech reported better-than-expected results for Q4FY23. The company posted a net profit of Rs 3,983 crore for the quarter, down 2.8% QoQ and up 11% YoY

Stocks to Watch: HCLTech, Cyient, Siemens, RIL, Suven Pharma, Voda Idea

Stocks to Watch: Check out the companies making headlines before the opening bell today.

Buzzing Stocks: RIL, HCL Tech, Cyient, Suven Pharma and others in the news today

The Competition Commission of India (CCI) on Thursday said it has cleared Berhyanda Ltd’s acquisition of a 76.10 per cent stake in pharmaceutical firm Suven Pharmaceuticals Ltd.

CCI clears Berhyanda’s 76% stake acquisition in Suven Pharmaceuticals

The acquisition is “by way of a share purchase agreement of December 26, 2022 and pursuant to the mandatory open offer in compliance with the Securities and Exchange Board of India (SEBI) (Substantial Acquisition of Shares and Takeovers) Regulations, 2011”, the competition regulator said in a statem…

CCI clears Berhyanda’s acquisition of Suven Pharma

CCI has approved the acquisition of up to 76.10 percent of the voting share capital of Suven Pharmaceuticals Limited by Berhyanda Limited.

CCI approves Berhyanda’s acquisition of Suven Pharma

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced and in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Not a good time to consider, stock is in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Suven Pharmaceuticals is engaged in  Contract Research and Manufacturing Services (CRAMS), Drug Discovery & Development Support Services (DDDSS), Drug Discovery & Research/Clinical Pipeline, and Formulation Development